This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Tildrakizumab pre-filled syringe

Updated 2 Feb 2023 | Tildrakizumab


Pre-filled syringe containing tildrakizumab.

Drugs List

  • ILUMETRI 100mg/1ml solution for injection pre-filled syringe
  • tildrakizumab 100mg/1ml solution for injection pre-filled syringe
  • Therapeutic Indications


    Moderate to severe plaque psoriasis

    Treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.



    Standard dose
    100mg at weeks 0, 4, and every 12 weeks thereafter.

    Higher dose (may be required by certain patients, such as those with a higher disease burden or a body weight above 90kg)
    200mg at weeks 0, 4, and every 12 weeks thereafter.

    Additional Dosage Information

    Consider discontinuing treatment in patients that do not respond after 28 weeks of treatment. Some patients with initial partial response may subsequently improve with continued treatment beyond 28 weeks.


    Administered via subcutaneous injection. Alternate injection sites, and do not inject into tender, bruised, red, hard, thick or scaly areas of skin, or areas affected by plaque psoriasis.


    Children under 18 years
    Severe infection
    Within 4 weeks of live viral or bacterial vaccination

    Precautions and Warnings

    Chronic infection
    History of recurrent infection
    Hepatic impairment
    History of tuberculosis
    Renal impairment

    Avoid live vaccines during and for 17 weeks after treatment
    Administration of live vaccines should occur 4 weeks before initiation
    Before starting therapy ensure immunisations are up to date
    Consider prophylactic anti-tuberculosis therapy if appropriate
    Treat and control infections prior to commencing therapy
    Record name and batch number of administered product
    Rotate injection site each day when injecting the same region
    Treatment to be administered by or under supervision of specialist
    Advise patient to report symptoms of infection immediately
    Advise patient to seek med advice if signs/symptoms of tuberculosis develop
    Consider stopping treatment if severe uncontrolled infections occur
    Oversuppression of immune system may increase susceptibility to infection
    Discontinue if hypersensitivity reactions occur
    Female: Contraception required during and for 17 weeks after treatment

    Each pre-filled syringe is for single use only.

    Pregnancy and Lactation


    Tildrakizumab is contraindicated during pregnancy.

    There is limited data on the use of tildrakizumab during pregnancy. Though there is no evidence of reproductive toxicity in animal studies, the manufacturer contraindicates the use of tildrakizumab during pregnancy as a precautionary measure.


    Tildrakizumab is contraindicated during breastfeeding.

    There is limited data on the use of tildrakizumab in breastfeeding. The manufacturer contraindicates the use of tildrakizumab in breastfeeding, stating that it is unknown whether the drug is excreted in breast milk, and a risk to the nursing infant cannot be excluded. Animal studies suggest that negligible amounts of the drug may be excreted in breast milk.

    LactMed suggests that the high molecular weight of tildrakizumab may limit the amount of the drug absorbed by the breastfed infant, and that it may be destroyed in the infant's gastrointestinal tract.

    Side Effects

    Back pain
    Pain / soreness (injection site)
    Upper respiratory tract infection


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2020

    Reference Sources

    Summary of Product Characteristics: Ilumetri 100mg solution for injection in pre-filled syringe. Almirall Limited. Revised January 2020.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Tildrakizumab Last revised: 3 December 2018
    Last accessed: 06 January 2020

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.